Multiple Dynamically-Coupled Binding Sites on Human Serum Albumin Regulate Estradiol's Nonlinear Binding

madman

Super Moderator
Dr. Bhasin and Dr. Jasuja most recent paper!

Estradiol binding to human serum albumin (HSA) is not a simple linear single-site interaction with a fixed dissociation constant (Kd) as assumed in traditional models (e.g., the Vermeulen/Södergård/Mazer equations for calculating free hormone fractions).

The linear law-of-mass action Vermeulen (cFTV) being the most widely used/relied on calculated method for free testosterone.

Estradiol's interaction with HSA is nonlinear and asymmetric, multi-site, dynamic and allosterically coupled.




* Estradiol's binding to HSA is a dynamic, multi-equilibrium process driven by ligand-induced conformational rearrangements within HSA; the binding data are inconsistent with canonical model of estradiol-HSA interaction with 1:1 stoichiometry and a fixed Kd.


* The traditional view characterizes estradiol binding to HSA as linear and governed by a significantly lower association constant compared to SHBG. (28,31,33,36-38) The oft-cited model developed by Vermeulen, Södergård, and Mazer assumes a simple bimolecular equilibrium between estradiol and HSA at a single binding site, 1:1 stoichiometry, and a fixed dissociation constant (Kd). Such assumptions have formed the basis of the published and widely used equations for calculations of free hormone fractions in plasma.(39) Emerging evidence, however, suggests that the interaction between estradiol and HSA may be more complex.(32,34,35,40-47) Our previous studies of testosterone's binding to HSA revealed multiple, allosterically-coupled binding sites for testosterone on HSA that testosterone shares with free fatty acids.(48) Our preliminary studies suggested that the binding isotherm of estradiol's interaction with HSA also is not linear. Similarly, Zeginiadou et al. reported that estradiol binds to HSA in a non-linear manner and its distribution depends on the relative concentrations of these proteins. (31,49)


* In (1), the bound (Fig. 1Ai) and free estradiol (Fig. 1Aii) increased with increasing estradiol concentration, allowing determination of apparent dissociation constant (Kd) for the overall binding. The apparent Kd varied dynamically with varying estradiol concentrations (Fig.1Aiii). In (2), the bound estradiol increased with increasing HSA concentration (Fig. 1Bi), with a corresponding decrease in free estradiol (Fig. 1Bii). The apparent Kd again varied dynamically with varying HSA concentration (Fig. 1Biii). These concentration-dependent changes in apparent Kd cannot be reconciled with the legacy linear binding model in which estradiol interacts with a single, fixed-affinity site on HSA, and instead support the presence of multiple binding sites with distinct affinities and/or ligand-induced intramolecular conformational rearrangements within HSA that dynamically modulate binding-site affinity. Consistent with this interpretation, the experimentally observed free estradiol concentrations in Fig. 1Aii and Fig. 1Bii deviate substantially from values predicted by a 1:1 stoichiometric binding model with a fixed Kd, as assumed in the Vermeulen model.



* Estradiol’s binding induces conformational rearrangements in HSA that contribute to the variable apparent Kds in the protein-ligand interaction and influence the strength and kinetics of the estradiol:HSA complex formation. The presence of multiple binding sites with graded affinities - a high-affinity site in Sudlow’s Site I and two additional moderate-affinity binding sites in a contiguous cluster - explains the concentration-dependent, non-saturating binding isotherms and the dynamically varying apparent Kd. Thus, estradiol's binding to HSA is not a simple 1:1 interaction but a coordinated, multi-site dynamic process facilitated by HSA's intrinsically connected structural architecture.








Figure 6. Docking-derived estradiol binding pockets and structural-block organization of human serum albumin (HSA).
(A–C) Top-ranked docking poses of estradiol bound to HSA. The ligand is shown in black stick representation. Predicted binding energies for the three highest-scoring pockets are: (A) −9.3 kcal/mol, (B) −8.8 kcal/mol, and (C) −8.7 kcal/mol. Pocket-lining residues are labelled to highlight key hydrophobic, aromatic, and charged interactions that contribute to ligand stabilization. (D) Structural-block (SB) interaction network derived from the residue–residue contact map of HSA. Nodes represent SB1–SB12, corresponding to spatially coherent residue clusters identified through network partitioning, and edges indicate significant inter-block contacts. The network highlights highly connected hubs that contribute to the protein’s internal structural communication. (E) Three-dimensional representation of HSA with structural blocks color-coded as in panel (D), showing their spatial distribution and continuity across the protein. This mapping provides the structural context for the ligand-binding pockets visualized in panels (A–C).
1774113506329.webp






Abstract

Background


Circulating estradiol is predominantly protein-bound, with human serum albumin (HSA) serving as its major carrier. While traditionally considered a carrier with low affinity and readily reversible binding at a single site, the molecular details and kinetics of estradiol-HSA interactions remain incompletely understood.


Methods

We employed equilibrium dialysis, steady-state and time-resolved fluorescence spectroscopy to characterize estradiol-HSA interactions. Surface plasmon resonance (SPR) was used to elucidate the kinetics of estradiol's association and dissociation with HSA. Structural and energetic features of binding were investigated using molecular docking and structure network analyses.


Results

Binding isotherms generated using equilibrium dialysis, steady-state and time-resolved fluorescence spectroscopy revealed non-linear asymmetric binding with apparent Kd that varied as a function of estradiol and HSA concentrations, inconsistent with canonical model of low-affinity, single-site interaction characterized by a fixed Kd. Kinetic analyses by SPR revealed initial rapid association dynamics followed by a slower second phase. Molecular modeling identified a high-affinity estradiol-binding pocket in Sudlow’s Site I and two additional low-affinity sites within a highly interconnected hub of structural blocks. Spatially coordinated conformational rearrangements accompanying estradiol partitioning into the high-affinity pocket of Sudlow’s Site I and two additional moderate-affinity sites suggest an allosterically coupled binding architecture that enables albumin to actively regulate estradiol bioavailability across a broad, physiologically relevant concentration range.


Conclusion

Estradiol's binding to HSA is a dynamic, multi-equilibrium process driven by ligand-induced conformational rearrangements within HSA; the binding data are inconsistent with canonical model of estradiol-HSA interaction with 1:1 stoichiometry and a fixed Kd.








Introduction

17β-estradiol is the principal estrogen and a key regulator of diverse physiological processes in women and men.(1-9) Under normal physiological conditions, the majority of estradiol circulates bound to carrier proteins such as sex hormone-binding globulin (SHBG) and human serum albumin (HSA), with only about 2–4% remaining in its free, unbound form.(10-15) The bioavailability of estradiol is governed by a dynamic equilibrium between its free and protein-bound forms, which is modulated by the relative concentrations and binding affinities of SHBG and HSA.(9,16-25) SHBG, owing to its high specificity and affinity for steroid hormones, is believed to serve as the principal regulator of this equilibrium.(12,26-29) HSA is reported to have substantially lower binding affinity for estradiol than SHBG and, in spite of its high plasma concentrations, its role in regulating estradiol's bioavailability and the dynamics of its binding to estradiol are incompletely understood.(12,30-35)

The traditional view characterizes estradiol binding to HSA as linear and governed by a significantly lower association constant compared to SHBG. (28,31,33,36-38) The oft-cited model developed by Vermeulen, Södergård, and Mazer assumes a simple bimolecular equilibrium between estradiol and HSA at a single binding site, 1:1 stoichiometry, and a fixed dissociation constant (Kd). Such assumptions have formed the basis of the published and widely used equations for calculations of free hormone fractions in plasma.(39) Emerging evidence, however, suggests that the interaction between estradiol and HSA may be more complex.(32,34,35,40-47) Our previous studies of testosterone's binding to HSA revealed multiple, allosterically-coupled binding sites for testosterone on HSA that testosterone shares with free fatty acids.(48) Our
preliminary studies suggested that the binding isotherm of estradiol's interaction with HSA also is not linear. Similarly, Zeginiadou et al. reported that estradiol binds to HSA in a non-linear manner and its distribution depends on the relative concentrations of these proteins. (31,49)

We used equilibrium dialysis and additional biophysical methods including fluorescence quenching, 4,4′-dianilino-1,1′-binaphthyl-5,5′-disulfonic acid (bis-ANS) displacement assay, and time resolved fluorescence spectroscopy to characterize the binding affinity and stoichiometry of estradiol’s binding with HSA. Experimental conditions, including temperature, pH, and buffer composition, were rigorously controlled and maintained constant throughout all assays to minimize confounding effects on protein-ligand interactions and ensure reproducibility.(42,45-47,50-53) The application of multiple orthogonal techniques enabled us to evaluate the conformity of the observed binding data with the legacy model of estradiol's binding with HSA proposed by Vermeulen, Sodergard, and Mazer which assumes a single binding site, 1:1 stoichiometry and a fixed dissociation constant (Kd).(39)

In addition, we characterized the kinetics of estradiol's association and dissociation with HSA using surface plasmon resonance (SPR). The prevailing concept of “bioavailable” estradiol, typically defined as the fraction of circulating estradiol not bound to SHBG, is based on the assumption that HSA binds estradiol with low affinity, allowing for rapid dissociation in tissue microenvironments. (28,30) Notably, the kinetic parameters governing estradiol-HSA interactions have not been measured using high-resolution temporal techniques. Our SPR experiments address this gap by providing the first direct kinetic analysis of estradiol binding to HSA.

Finally, we used molecular docking simulations and structure network analysis to further characterize the dynamics of estradiol's binding to HSA and provide important structural energetic, and mechanistic insights into estradiol-binding sites on HSA. Docking simulations identified multiple binding sites, with the top-ranked pose indicating a strong interaction. The structure network analysis highlighted HSA’s adaptability in accommodating estradiol and potential conformational changes influencing the binding affinity. Collectively, the data reported in this manuscript provide important insights into the dynamics and kinetics of estradiol's binding to HSA and conformational coupling across binding pocket residues in the HSA:estradiol complex.





Results

Binding isotherms generated using equilibrium dialysis do not conform to a single-site linear binding model with a fixed Kd


We used equilibrium dialysis to characterize the binding of estradiol to HSA, measuring the bound and free estradiol concentrations in two formats: 1) keeping the HSA concentration fixed at 500 µM (near physiological) and varying the estradiol concentration; or 2) keeping estradiol concentration fixed at 50 nM and varying the HSA concentration.

In (1), the bound (Fig. 1Ai) and free estradiol (Fig. 1Aii) increased with increasing estradiol concentration, allowing determination of apparent dissociation constant (Kd) for the overall binding. The apparent Kd varied dynamically with varying estradiol concentrations (Fig.1Aiii). In (2), the bound estradiol increased with increasing HSA concentration (Fig. 1Bi), with a corresponding decrease in free estradiol (Fig. 1Bii). The apparent Kd again varied dynamically with varying HSA concentration (Fig. 1Biii). These concentration-dependent changes in apparent Kd cannot be reconciled with the legacy linear binding model in which estradiol interacts with a single, fixed-affinity site on HSA, and instead support the presence of multiple binding sites with distinct affinities and/or ligand-induced intramolecular conformational rearrangements within HSA that dynamically modulate binding-site affinity. Consistent with this interpretation, the experimentally observed free estradiol concentrations in Fig. 1Aii and Fig. 1Bii deviate substantially from values predicted by a 1:1 stoichiometric binding model with a fixed Kd, as assumed in the Vermeulen model.





Conclusion

The integrated computational and experimental approach demonstrates that estradiol binding to HSA occurs through a coordinated, concentration-dependent engagement of multiple structurally-linked binding pockets organized around a central hub. This model successfully explains the full spectrum of non-linear binding behaviour. Estradiol’s binding induces conformational rearrangements in HSA that contribute to the variable apparent Kds in the protein-ligand interaction and influence the strength and kinetics of the estradiol:HSA complex formation. The presence of multiple binding sites with graded affinities - a high-affinity site in Sudlow’s Site I and two additional moderate-affinity binding sites in a contiguous cluster - explains the concentration-dependent, non-saturating binding isotherms and the dynamically varying apparent Kd. Thus, estradiol's binding to HSA is not a simple 1:1 interaction but a coordinated, multi-site dynamic process facilitated by HSA's intrinsically connected structural architecture.
 
Fig. 1: (A) The binding isotherms generated at varying estradiol concentrations (1.5 to 800 nM) and a fixed HSA (500 µM) concentration (each data point represents the mean+/-SD, 3 experiments). Increasing concentrations of estradiol were incubated with 500 µM HSA for 24 hours in the dialysis chambers and bound estradiol (left panel, Ai) or free estradiol (middle panel, Aii) at equilibrium were plotted against the total estradiol concentration. The right panel (Aiii) illustrates the varying apparent Kd at various estradiol concentrations and 500 µM HSA. (B) Binding isotherms generated at varying HSA concentrations (0.5 to 500 µM) and a fixed estradiol (50 nM) concentration (each data point represents the mean+/-SD, 3 experiments). Increasing concentrations of HSA were incubated with 50 nM estradiol for 24 hours in the dialysis chambers and bound estradiol (left panel, Bi)) or free estradiol (middle panel, Bii)) concentrations at equilibrium were plotted against the total HSA concentration. The right panel (Biii) illustrates the varying apparent Kd at various HSA concentrations and 50 nM estradiol. The binding isotherms predicted by the linear Vermeulen model with a fixed Kd are shown in red dots in both middle panels. Red dotted horizontal line in both right panels represents Kd value calculated using the Vermeulen fixed Kd, single site binding model (22.8 µM). The differences in Kds across conditions were analysed using a one-way analysis of variance (ANOVA), followed by Tukey’s post hoc test to evaluate differences of Kd at each concentration vs the lowest concentration while controlling the family-wise error rate. *P≤ 0.05; **P≤ 0.01; ***P≤ 0.001; ns P > 0.05; reference point.

1774114100414.webp
 
Fig. 2: Steady-state fluorescence spectroscopy shows the binding of estradiol affects the microenvironment of trp-214 in HSA. (A) Emission spectra of HSA (30 µM) titrated with increasing concentration of estradiol (0-99 µM), showing concentration-dependent changes. Black shows the measured spectra, which quench and blue-shift with increased estradiol. Blue and red, respectively, show the decomposition into two spectral components revealed by nonnegative matrix factorization. The short wavelength component (component 1) increases as the long wavelength component (component 2) decreases. (B) Stern-Volmer style plots of the fluorescence intensity of the total (black, close-up in inset) spectrum and each spectral component (blue,1;red,2). For each, lines fit for concentrations below 30µM illustrate the deviations from linearity at higher values. (C) Summed delta intensity plots for the total fluorescence (black) and 2nd component (red). For each, dotted lines represent a fit to the Vermeulen model (Kd=22.87µM), showing clear discordance. Solid curves show fits to a 1:1 model with Kd left as a free parameter (KdTotal= 140µM, KD2=232µM).

1774114657292.webp
 
Fig. 3 (A) Emission spectra following the repartitioning of non-specific extrinsic probe Bis-ANS (10 µM): Before addition of 1 µM HSA (red) and after (black), showing the appearance of a strong emission due to Bis-ANS partitioning into hydrophobic pockets in HSA. (B) Quenching of Bis-ANS emission after sequential additions of estradiol (0- ~20 µM), caused by estradiol displacing the Bis-ANS. (C) Summed change in emission intensity, with fitted models. The red curve represents the best fit to a 1:1 Vermeulen binding model with Kd= 22.87 µM, which fits poorly. The blue curve shows an unconstrained fit to 1:1 model, which yielded a KD of 8.4 µM. The fit is reasonable but evidently shows non-random residuals.

1774114976130.webp
 
Fig. 4: Fluorescence lifetime analysis using the intrinsic fluorescence of HSA (30µM); n=2. (A) The phase delay and modulation ration for the excited state emission. These data are fit to multi-component decay model in a least-squares method to yield the fluorescence lifetime information. (B) Change in lifetime of short- and long-lifetime components upon estradiol’s binding. (C) Reduction in average lifetime ((Σiτiαi)/(Σiαi)) in respect of increasing concentration of estradiol (0- 70µM). (D) Relative changes in the lifetime of short- and long-lifetime components with increasing estradiol concentration (0-70µM). (E) Change in fractional contribution from short- and long-lifetime component in average lifetime with increasing estradiol concentrations (0-70µM). (F) Relative change in fractional contribution from short and long lifetime component in average lifetime with increasing estradiol concentrations (0-70µM).

1774115188638.webp
 
Fig. 5: (A) SPR sensorgrams of estradiol binding to HSA measured using the Biacore T200 instrument, after reference cell subtraction and blank subtraction, measured with 10Hz resolution. Analyte injection began at 0s, and the response prior to this was set to zero. Running buffer is injected at 60s, causing dissociation of estradiol from the immobilized protein. Inset shows the lower concentration values, 3.125µM and below. (B) The equilibrium RU values, found as the average of the final 10s, as a function of estradiol concentration. The line shows a fit to a single-site model which furnished a dissociation constant of 110 µM +/- 23 µM. Error bars on the points (standard deviation of the final 10s of each trace) are, in most cases, smaller than the size of the markers.

1774115348618.webp
 
 

ExcelMale Newsletter Signup

Online statistics

Members online
6
Guests online
300
Total visitors
306

Latest posts

Beyond Testosterone Podcast

Back
Top